SMS Pharmaceuticals has received a non-exclusive licence to manufacture and supply of nirmatrelvir through the Medicine Patent Pool to manufacture nirmatrelvir, an oral anti-viral COVID-19 medicine developed by Pfizer to increase broad access of treatment in 95 low and middle income countries.
SMS Pharmaceuticals is a global player in API and intermediates manufacturing having a strong research and manufacturing team supported by state?of?the?art facilities.